Pfizer and BioNTech announce early positive data from ongoing phase 1/2 study of mRNA-based vaccine candidate (BNT162b1) against SARS-CoV-2

Preliminary data from initial part of study (n=45 healthy adults aged 18 to 55 years) provide a signal that BNT162b1 targeting the receptor binding domain of SARS-CoV-2 is able to produce neutralising antibody responses in humans at or above levels observed in convalescent sera.


Biospace Inc.